SCHEMBL3785291

SCHEMBL3785291

COC(=O)COc1ccc(F)c2nc(C)c(Cc3ccc(Cl)cc3)c(OC(F)F)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.50
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
P2RX3 P56373 6/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
HIF1A Q16665 1/20 0.34
PTGDR Q13258 1/20 0.34
KMT2A Q03164 1/20 0.34
PLA2G2A P14555 2/20 0.34
PTGS2 P35354 1/20 0.34
ESR1 P03372 1/20 0.34
POLB P06746 1/20 0.34
ESR2 Q92731 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MBOAT4 Q96T53 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3772144 0.93 PTGDR2 (0.43) PTGDR2KDM4EALDH1A1ALOX15MAPK1
SCHEMBL3772687 0.91 PTGDR2 (0.59) PTGDR2P2RX3TDP1
SCHEMBL3782624 0.89 PTGDR2 (0.63) PTGDR2KDM4EALDH1A1P2RX3PTGDR
SCHEMBL3771722 0.88 PTGDR2 (0.44) PTGDR2KDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL3783447 0.85 PTGDR2 (0.43) PTGDR2P2RX3PTGDRPLA2G2APTGS2
SCHEMBL3780089 0.84 PTGDR2 (0.39) PTGDR2KDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL3772870 0.83 PTGDR2 (0.51) PTGDR2KDM4EP2RX3TDP1MBOAT4
SCHEMBL3772517 0.83 PTGDR2 (0.66) PTGDR2KDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL3772684 0.82 PTGDR2 (0.54) PTGDR2KDM4EALDH1A1L3MBTL1P2RX3
SCHEMBL3776193 0.82 KDM4E (0.39) PTGDR2KDM4EALDH1A1ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 PTGDR2 146/4885KDM4E 4638/4885ALDH1A1 4201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.